近期论文
查看导师新发文章
(温馨提示:请注意重名现象,建议点开原文通过作者单位确认)
Gauthier, S., Feldman, HH., Schneider, LS., Wilcock, GK., Frisoni, GB., Hardlund, JH., Moebius, HJ., Bentham, P., Kook, KA., Wischik, DJ., Schelter, BO., Davis, CS., Staff, RT., Bracoud, L., Shamsi, K., Storey, JMD., Harrington, CR. & Wischik, CM. (2016). 'Efficacy and safety of tau-aggregation inhibitor therapy in patients with mild or moderate Alzheimer's disease: a randomised, controlled, double-blind, parallel-arm, phase 3 trial'. The Lancet, vol 388, no. 10062, pp. 2873-2884. DOI: [ONLINE] DOI: 10.1016/S0140-6736(16)31275-2
?imi?, G., Leko, MB., Wray, S., Harrington, CR., Delalle, I., Jovanov-Milo?evi?, N., Ba?adona, D., Buée, L., Silva, RD., Giovanni, GD., Wischik, CM. & Hof, PR. 'Monoaminergic Neuropathology in Alzheimer's disease'. Progress in Neurobiology. DOI: [ONLINE] DOI: 10.1016/J.PNEUROBIO.2016.04.001
Lai, RYK., Harrington, CR. & Wischik, CM. (2016). 'Absence of a Role for Phosphorylation in the Tau Pathology of Alzheimer's Disease'. Biomolecules, vol 6, no. 2, 19. DOI: [ONLINE] DOI: 10.3390/BIOM6020019 [ONLINE] AURA: BIOMOLECULES_06_00019_V2.PDF
Melis, V., Magbagbeolu, M., Rickard, JE., Horsley, D., Davidson, K., Harrington, KA., Goatman, K., Goatman, EA., Deiana, S., Close, SP., Zabke, C., Stamer, K., Dietze, S., Schwab, K., Storey, JMD., Harrington, CR., Wischik, CM., Theuring, F. & Riedel, G. (2015). 'Effects of oxidized and reduced forms of methylthioninium in two transgenic mouse tauopathy models'. Behavioural Pharmacology, vol 26, no. 4, pp. 353-368. DOI: [ONLINE] DOI: 10.1097/FBP.0000000000000133 [ONLINE] AURA: EFFECTS_OF_OXIDIZED_AND_REDUCED_FORMS_OF.4.PDF
Melis, V., Zabke, C., Stamer, K., Magbagbeolu, M., Schwab, K., Marshall, P., Weh, RW., Bachmann, S., Deiana, S., Moreau, PH., Davidson, K., Harrington, KA., Rickard, JE., Horsley, D., Garman, R., Mazurkiewicz, M., Niewiadomska, G., Wischik, CM., Harrington, CR., Riedel, G. & Theuring, F. (2015). 'Different pathways of molecular pathophysiology underlie cognitive and motor tauopathy phenotypes in transgenic models for Alzheimer’s disease and frontotemporal lobar degeneration'. Cellular and Molecular Life Sciences, vol 72, no. 11, pp. 2199-2222. DOI: [ONLINE] DOI: 10.1007/S00018-014-1804-Z [ONLINE] AURA: ART_3A10.1007_2FS00018_014_1804_Z.PDF
Harrington, CR., Storey, JMD., Clunas, S., Harrington, KA., Horsley, D., Ishaq, A., Kemp, SJ., Larch, CP., Marshall, C., Nicoll, SL., Rickard, JE., Simpson, M., Sinclair, JP., Storey, LJ. & Wischik, CM. (2015). 'Cellular Models of Aggregation-Dependent Template-Directed Proteolysis to Characterize Tau Aggregation Inhibitors for Treatment of Alzheimer's Disease'. The Journal of Biological Chemistry, vol 290, no. 17, pp. 10862-10875. DOI: [ONLINE] DOI: 10.1074/JBC.M114.616029 [ONLINE] AURA: J._BIOL._CHEM._2015_HARRINGTON_10862_75.PDF
Flores-Rodríguez, P., Ontiveros-Torres, MA., Cárdenas-Aguayo, MC., Luna-Arias, JP., Meraz-Ríos, MA., Viramontes-Pintos, A., Harrington, CR., Wischik, CM., Mena, R., Florán-Gardu?o, B. & Luna-Mu?oz, J. (2015). 'The relationship between truncation and phosphorylation at the C-terminus of tau protein in the paired helical filaments of Alzheimer's disease'. Frontiers in Neuroscience, vol 9, 33. DOI: [ONLINE] DOI: 10.3389/FNINS.2015.00033 [ONLINE] AURA: FNINS_09_00033.PDF
Baddeley, TC., McCaffrey, J., Storey, JMD., Cheung, JKS., Melis, V., Horsley, D., Harrington, CR. & Wischik, CM. (2015). 'Complex Disposition of Methylthioninium Redox Forms Determines Efficacy in Tau Aggregation Inhibitor Therapy for Alzheimer's Disease'. Journal of Pharmacology and Experimental Therapeutics, vol 352, no. 1, pp. 110-118. DOI:[ONLINE] DOI: 10.1124/JPET.114.219352
Wischik, CM., Staff, RT., Wischik, DJ., Bentham, P., Murray, AD., Storey, JMD., Kook, KA. & Harrington, CR. (2015). 'Tau Aggregation Inhibitor Therapy: An Exploratory Phase 2 Study in Mild or Moderate Alzheimer's Disease'. Journal of Alzheimer's Disease, vol 44, no. 2, pp. 705-720. DOI: [ONLINE] DOI: 10.3233/JAD-142874 [ONLINE] AURA: FULLTEXT.PDF
Wischik, CM., Harrington, CR. & Storey, JMD. (2014). 'Tau-aggregation inhibitor therapy for Alzheimer's disease'. Biochemical Pharmacology, vol 88, no. 4, pp. 529-539. DOI: [ONLINE] DOI: 10.1016/J.BCP.2013.12.008 [ONLINE] AURA: 1_S2.0_S0006295213007612_MAIN.PDF